C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer by Beneš, Petr et al.
Introduction
The low-density lipoprotein receptor-related protein 1
(LRP1, ID 6692 in the Human Gene Nomenclature data-
base) is a member of the low-density lipoprotein receptor
(LDLR) family [1]. Receptors of this family mediate the
internalization of a variety of extracellular macromolecules
and macromolecular complexes, including lipoproteins,
proteinases, proteinase–inhibitor complexes and extracel-
lular matrix proteins [2]. Recent studies have demon-
strated that several receptors of this family are also
involved in ligand-mediated signal transduction [3].
LRP1 is a large endocytic receptor that recognizes more
than 30 different ligands. Proteinases and molecules asso-
ciated with the regulation of proteolytic activity are the
largest group of LRP1 ligands. Certain proteinases bind
directly to LRP1, whereas several other proteinases only
bind once complexed with their specific inhibitors [2].
LRP1 is involved in the tight regulation of serine pro-
teinases of the plasminogen/plasmin system and also in
the regulation of certain matrix metalloproteinase family
members [1,4,5]. Through the regulation of extracellular
proteolytic activity, LRP1 has an important role in the regu-
lation of cellular growth, cell migration, tissue repair and
remodeling, and tumor progression and invasion [1,3,6].
In addition, it has been shown that LRP1 is a signaling
receptor involved in inositol and Wnt signaling, Ras activa-
tion and the activation of Src, mitogen-activated protein
kinases and protein kinase A. Although the function of
JNK = c-Jun amino-terminal kinase; LRP1 = low-density lipoprotein receptor-related protein 1; LDLR = low-density lipoprotein receptor; PCR =
polymerase chain reaction; uPA = urokinase plasminogen activator.
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Background: Low-density lipoprotein receptor-related protein 1
(LRP1) is a multifunctional endocytic receptor with an
important role in regulating the activity of proteinases in
extracellular matrix. Several studies have also described its role
in intracellular signaling. Previous studies showed that the
expression of LRP1 is related to invasiveness of cancer cells.
However, recent data on LRP1 suggest that this receptor can
also be involved in tumor establishment and progression.
Methods: We investigated an association between the C766T
polymorphism of the third exon of the LRP1 gene and breast
cancer in a sample of women of Caucasian origin. Allele and
genotype frequencies of this polymorphism were assessed in
164 women with breast cancer and in 183 age-compatible
women without a history of any cancer disease.
Results: An increase in LRP1 T allele frequency in subjects
with breast cancer was observed compared with controls (0.21
versus 0.15, P=0.01963). A significant excess of genotypes
with the T allele (homozygotes plus heterozygotes) was also
observed (odds ratio 1.743, 95% confidence interval
1.112–2.732).
Conclusion: The T allele of the C766T polymorphism in the
LRP1 gene is associated with an increased risk of breast
cancer development in women of Caucasian origin.
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LRP1 in these processes is less well understood, several
authors have suggested that LRP1 might modulate mito-
genic signaling, cell adhesion, cell proliferation and apop-
tosis [3,7,8].
Besides the role of LRP1 in protease regulation and cell
signaling, Binder and colleagues [9] also suggested that it
acts, through the binding of the heat shock protein gp96
on the surface of antigen-presenting cells, as a sensor for
necrotic cell death leading to proinflammatory immune
responses.
Because of its potential role in processes mentioned
above, the relationship between LRP1 expression and
cancer establishment, progression and invasion has been
studied. Increased expression of LRP1 has been shown in
human malignant astrocytes and the glioblastoma cell line
U87 [10,11]. In addition, Li and colleagues [6] observed
that LRP1 promotes invasiveness of breast cancer cells
in vitro. However, previous studies also showed that LRP1
expression decreases with aggressiveness in several
human tumor cell lines (lung carcinoma, osteosarcoma)
compared with nontumor cell lines [12,13].
In addition, LRP1 gene amplification has been observed in
some astrocytomas [14], and Grimsley and colleagues
[15] reported that the concentration of LRP1 protein
increases with the passage number of cultured Hep G2
hepatoma cells, possibly owing to the selection of cells
with LRP1 gene amplification. Another interesting finding
has recently been observed [16,17]: in these papers it
was suggested that LRP1B, a member of the LDLR family
with striking homology to LRP1, represents a tumor sup-
pressor gene in non-small cell lung cancer cell lines [16]
and urothelial cancer cells [17]. In their studies the
authors reported frequent alteration of the LRP1B gene in
non-small cell lung cancer cell lines and urothelial cancer
cells, respectively.
The common silent C766T polymorphism in exon 3 of the
LRP1 gene has been associated with Alzheimer’s disease
[18,19], suggesting that this polymorphism might be of
functional importance or might be a marker of other func-
tional changes located in this gene. Our study was under-
taken to investigate an association between the C766T
LRP1 polymorphism and the occurrence of breast cancer
in a sample of Czech women of Caucasian origin.
Materials and methods
Subjects
The populations tested comprised 164 females diagnosed
with breast cancer (mean age 57 years, range
35–80 years), as a control population, and 183 age-com-
patible female volunteers (mean age 57 years, range
40–94 years) with no history of cancer of any type. The
cancer patients were recruited in collaboration with
several oncologists and surgeons in the city of Brno,
Czech Republic. All cancers were confirmed histologically.
The control subjects were also recruited from several dis-
tricts of the city of Brno by general practitioners from their
clientele. Both the patients and the controls were unre-
lated Caucasians of Czech nationality. The study was
approved by the Committee for Ethics of Medical Experi-
ments on Human Subjects, Medical Faculty, Masaryk Uni-
versity, Brno.
Methods
Genomic DNA was extracted from peripheral blood leuko-
cytes. The LRP1 C766T genotypes were determined by
polymerase chain reaction (PCR) and a subsequent
restriction analysis with RsaI restriction endonuclease as
described by Hollenbach and colleagues [19]. PCR was
performed in a total volume of 25µl containing 50ng of
genomic DNA, 10pmol of each primer (5′-
GGGGTCCAGGACTGCATGTA-3′ and 5′-AAGTCCG-
TACCTCGGCAGTG-3′), 1 × reaction buffer (MBI
Fermentas, Vilnius, Lithuania), 200µM deoxyribonu-
cleotides (Roche Diagnostics, Mannheim, Germany),
3.0mM Mg2+ and 0.2 units of Taq polymerase (Fermen-
tas). The amplification conditions were as follows: initial
denaturation at 95°C for 3 min, followed by 34 cycles of
denaturation at 94°C for 30s, annealing at 54°C for 30s,
elongation at 72°C for 20s and final elongation at 72°C
for 2 min. PCR products were digested with 5 units of
RsaI (Fermentas). Digested fragments were separated on
4.0% MetaPhor agarose gels and detected by ethidium
bromide staining. The presence of the T allele was charac-
terized by fragments of 51 and 8 base pairs, the presence
of the C allele by fragments of 32, 19 and 8 base pairs.
Statistical analysis
Differences in genotype distributions from those expected
for Hardy–Weinberg equilibrium were tested by the χ2
test. The significances of differences in allele frequencies
among groups were tested by Fisher’s exact test. Odds
ratios and 95% confidence intervals were calculated.
P<0.05 was considered statistically significant. For all
statistical analyses, the data analysis software system
STATISTICA, version 6 (StatSoft, Inc; www.statsoft.com)
was used.
Results
Allele frequencies and genotype distribution of the C766T
LRP1 polymorphism in the breast cancer and the control
groups are shown in Table 1. The distribution of geno-
types in the breast cancer and the control groups did not
differ from Hardy–Weinberg equilibrium. The distribution
of alleles in the control group is identical with that previ-
ously reported in control subjects from the same Cau-
casian population [20]. The LRP1 T allele frequency was
significantly higher in women with breast cancer than in
the control subjects (0.21 versus 0.15; P=0.01963). TheR79
combined number of subjects with the T allele (CT hetero-
zygotes and TT homozygotes) was significantly higher in
the breast cancer subjects than in the controls (odds ratio
1.743, 95% confidence interval 1.112–2.732).
Discussion
Tumorigenesis is a multistep process that involves cell
transformation, invasive growth, angiogenesis and spread
of the tumor into distant sites [21]. It has previously been
suggested that LRP1 is involved in the regulation of some
of these processes.
The breakdown of the basement membrane and extracel-
lular matrix facilitates cancer cell invasion and migration
into the surrounding normal tissues [22]. This critical step
in cancer progression is mediated by serine proteinases
and metalloproteinases [23]. It has been demonstrated
that LRP1 modulates the extracellular levels of several
matrix metalloproteinases [4,5] as well as the extracellular
level of urokinase plasminogen activator (uPA), a serine
proteinase that activates plasminogen [2]. Extracellular
proteolytic activity is an important factor in cancer estab-
lishment and progression [24–26]. However, recent
studies indicate that proteinases participate not only in
cancer progression and metastasis but that they are
important in all stages of tumorigenesis including tumor
establishment, growth and neovascularization [25]. Degra-
dation of the extracellular matrix mediated by these pro-
teinase systems perturbs cellular signaling, interferes with
the adhesiveness of cells and activates several growth
factors, all of which processes are important in tumorigen-
esis [25–27].
Lutz and colleagues [7] have recently shown that LRP1
modulates the mitogen-induced c-Jun amino-terminal
kinase (JNK) signaling pathway and therefore the tran-
scriptional activity of the transcription factor activator
protein 1 (AP-1), which has been implicated in a variety of
biological processes including cell proliferation, apoptosis
and oncogenic transformation [28]. Moreover, Lutz and
colleagues found that the expression of a fusion protein
bearing the intracellular carboxy-terminal tail of human
LRP1 and the transmembrane region plus the extracellular
IgG-Fc domain selectively reduced DNA-damage-induced
apoptosis in neuronal cells. The authors suggested that
LRP1 is involved, by modulating the JNK signaling trans-
duction pathway, in apoptotic and stress responses [7].
JNK lies downstream in the Ras signaling pathway. Ras
proteins are key transducers of growth signals regulated
by receptors on the cell surface [29]. Recent studies have
shown that the phosphorylated cytoplasmic tail of LRP1
associates both in vivo and  in vitro with the cellular
docking protein Shc [30]. It has been suggested that this
association is important for the phosphorylation of Shc.
Phosphorylated Shc proteins are important mediators of
Ras activation. Phosphorylation of tyrosine residues of
LRP1 is thus believed to be involved in signal transduc-
tion. The role of LRP1 in other types of cell signaling has
been also suggested [3,8].
Our study was designed to investigate the role of C766T
LRP1 polymorphism in breast cancer development. We
observed that the LRP1 T allele frequency was signifi-
cantly higher in patients with breast cancer than in the age
and sex-compatible control subjects. These findings imply
that female bearers of the LRP1 T allele are more suscep-
tible to breast cancer development than women with the
LRP1 CC genotype. However, large studies will be
needed to confirm this finding.
We are aware that association studies have several limita-
tions. The heterogeneity between patients and control
subjects in terms of age and ethnicity could explain false
positive results. Moreover, small population-based
samples might not be representative in terms of the allele
and genotype frequencies of whole population. However,
it seems that this is not true of this study. Patient and
control subjects were age-compatible unrelated Cau-
casians recruited from a homogenous Czech population.
Moreover, the LRP1 T allele frequency of the control
group from this study is almost identical with that previ-
ously observed in a large sample of subjects from the
same Caucasian population [20]. The fact that allele and
genotype frequencies in all samples studied did not differ
from Hardy–Weinberg equilibrium also suggests that the
observed allele and genotype frequencies are representa-
tive of the Czech population.
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Table 1
Distribution of genotypes and allele frequencies of the LRP1 C766T polymorphism in both breast cancer and control groups
Genotypes Allele frequencies
Group nC C C T T TC T P
Controls 183 132 47 4 0.85 0.15
Breast cancer 164 98 62 4 0.79 0.21 0.01963Breast Cancer Research    Vol 5 No 3 Beneš et al.
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Previous reports suggested that LRP1 promotes invasive-
ness of breast cancer cells in vitro [6] and that the expres-
sion of LRP1 in human breast cancer cells is induced by
hypoxia [31], estrogen and cell density [32]. In addition,
Chazaud and colleagues [33] reported that uPA and
LRP1 are localized at filopodia of invasive breast cancer
cells, and that the formation/internalization of a complex of
LRP1 with uPA, uPA receptor and plasminogen activator
inhibitor-1 is required for the attachment and migration of
cancer cells in vitro.
So far, little is known about the functional importance of
the silent C766T LRP1 polymorphism. Numerous studies
have associated this polymorphism with an increased risk
of Alzheimer’s disease [18,19] suggesting that this poly-
morphism is probably a marker of other functional changes
located in this gene. However, although the C766T poly-
morphism causes neither an amino acid change nor an
alteration of a consensus splicing site, we cannot discount
the C766T variant as a neutral polymorphism. A functional
LRP1 polymorphism could (1) influence the expression of
the LRP1 gene and thus the number of LRP1 receptors
on the cell surface, (2) influence the affinity of LRP1 for its
ligands and thus the uptake of several proteases and their
inhibitors, and (3) alter the signaling activity of LRP1. The
exact role of the C766T polymorphism in LRP1 remains to
be resolved.
Conclusion
The results of this study indicate that the T allele of the
C766T polymorphism in the LRP1 gene is associated with
an increased risk of breast cancer development in female
Caucasian subjects. Further studies are needed to estab-
lish an influence of this and other LRP1 polymorphisms on
LRP1 gene expression and/or protein function. The role of
LRP1 polymorphisms in other types of cancer also
remains to be solved.
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